(UroToday.com) Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) have rapidly evolved over the past 15 years. In 2004, Dr. Tannock reported results of the TX-327 trial which demonstrated improved overall survival for patients with mCRPC who received docetaxel, the first such evidence supporting life prolonging therapy in this disease space. Since then, a number of other studies have demonstrated survival benefits with the use of abiraterone acetate, enzalutamide, cabazitaxel, radium-223, immunotherapy, and PARP inhibitors have been reported in randomized controlled trials.